These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36971051)

  • 1. Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.
    Gao F; Hu K; Zheng P; Shi H; Ke X
    Cancer Med; 2023 May; 12(9):10267-10279. PubMed ID: 36971051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
    Zhou LH; Feng YQ; Hu YX; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of
    Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
    J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of
    Porpaczy E; Wohlfarth P; Königsbrügge O; Rabitsch W; Skrabs C; Staber P; Worel N; Müllauer L; Simonitsch-Klupp I; Kornauth C; Rohrbeck J; Jaeger U; Schiefer AI
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
    Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.
    Broccoli A; Casadei B; Chiappella A; Visco C; Tani M; Cascavilla N; Conconi A; Balzarotti M; Cox MC; Marino D; Goldaniga MC; Marasca R; Tecchio C; Patti C; Musuraca G; Devizzi L; Monaco F; Romano A; Fama A; Zancanella M; Paolini R; Rigacci L; Castellino C; Gaudio F; Argnani L; Zinzani PL
    Oncologist; 2019 Sep; 24(9):1246-1252. PubMed ID: 30940746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
    Dang X; Ye S; Zhou L; Lu Y; Li P; Liang A; Qian W
    Cytotherapy; 2023 Jun; 25(6):573-577. PubMed ID: 36456447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
    Kong D; Ping N; Gao X; Zou R; Wang P; Wu D; Jin Z; Qu C
    Front Immunol; 2023; 14():1200748. PubMed ID: 37292195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.
    Zhang Q; Zhu X; Liu B; Zhang Y; Xiao Y
    Front Immunol; 2023; 14():1127868. PubMed ID: 37006273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.
    Morin RD; Assouline S; Alcaide M; Mohajeri A; Johnston RL; Chong L; Grewal J; Yu S; Fornika D; Bushell K; Nielsen TH; Petrogiannis-Haliotis T; Crump M; Tosikyan A; Grande BM; MacDonald D; Rousseau C; Bayat M; Sesques P; Froment R; Albuquerque M; Monczak Y; Oros KK; Greenwood C; Riazalhosseini Y; Arseneault M; Camlioglu E; Constantin A; Pan-Hammarstrom Q; Peng R; Mann KK; Johnson NA
    Clin Cancer Res; 2016 May; 22(9):2290-300. PubMed ID: 26647218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis.
    Kittai AS; Huang Y; Gordon M; Denlinger N; Mian A; Fitzgerald L; Bishop J; Nagle S; Stephens DM; Jaglowski S; Hill B; Danilov AV
    Transplant Cell Ther; 2021 Jan; 27(1):46-52. PubMed ID: 33002640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
    Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
    Front Immunol; 2022; 13():969660. PubMed ID: 36059523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review.
    Tian L; Li C; Sun J; Zhai Y; Wang J; Liu S; Jiang Y; Wu W; Xing D; Lv Y; Guo J; Xu H; Sun H; Li Y; Li L; Zhao Z
    Front Immunol; 2022; 13():1041177. PubMed ID: 36733398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.
    Wei J; Xiao M; Mao Z; Wang N; Cao Y; Xiao Y; Meng F; Sun W; Wang Y; Yang X; Chen L; Zhang Y; Zhu H; Zhang S; Zhang T; Zhou J; Huang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):101. PubMed ID: 35399106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma.
    Forberg AL; Unrau J; Weber KS; Rutz AC; Lund S; Guidinger J; Pelzel A; Hauge J; Hemmen AJ; Hartert KT
    Ann Hematol; 2024 Jan; 103(1):199-209. PubMed ID: 37792064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
    Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
    Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
    Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
    Front Immunol; 2022; 13():879030. PubMed ID: 35558072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
    Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
    Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells.
    Lu Y; Zhu H; Liu Y; Wang Y; Sun Y; Cheng H; Yan Z; Cao J; Sang W; Zhu F; Li D; Sun H; Zheng J; Xu K; Li Z
    Front Immunol; 2023; 14():1155216. PubMed ID: 37205117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.